GE HealthCare Technologies (GEHC)
Market Price (6/20/2026): $61.38 | Market Cap: $28.0 BilInvestor Relations Sector: Health Care | Industry: Health Care Equipment
GE HealthCare Technologies (GEHC)
Market Price (6/20/2026): $61.38Market Cap: $28.0 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.0%, FCF Yield is 5.4% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -26% Attractive cash flow generationCFO LTM is 2.0 Bil Low stock price volatilityVol 12M is 32% Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -58%, 3Y Excs Rtn is -92% | Key risksGEHC key risks include [1] playing catch-up to competitors in advanced technologies like photon-counting CT and [2] execution risks in successfully integrating its AI and digital transformation initiatives. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.0%, FCF Yield is 5.4% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -26% |
| Attractive cash flow generationCFO LTM is 2.0 Bil |
| Low stock price volatilityVol 12M is 32% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -58%, 3Y Excs Rtn is -92% |
| Key risksGEHC key risks include [1] playing catch-up to competitors in advanced technologies like photon-counting CT and [2] execution risks in successfully integrating its AI and digital transformation initiatives. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 6/1/2026
GE HealthCare Technologies (GEHC) stock has lost about 25% since 2/28/2026 because of the following key factors:
1. GE HealthCare reported a Q1 2026 earnings per share (EPS) miss and subsequently Show more
GE HealthCare Technologies (GEHC) stock has lost about 25% since 2/28/2026 because of the following key factors:
1. GE HealthCare reported a Q1 2026 earnings per share (EPS) miss and subsequently Show more
Updated on 6/1/2026
GE HealthCare Technologies (GEHC) stock has lost about 25% since 2/28/2026 because of the following key factors:
1. GE HealthCare reported a Q1 2026 earnings per share (EPS) miss and subsequently reduced its full-year 2026 profit outlook. The company announced on April 29, 2026, that its Q1 2026 adjusted EPS was $0.99, missing the consensus estimate of $1.07 by $0.08, or 7.5%. Following this, GE HealthCare cut its full-year adjusted EPS guidance to a range of $4.80-$5.00, down from its previous expectation of $4.95-$5.15. This downward revision implied a lower year-over-year growth rate for adjusted EPS, projected at 4.6%-9.0% compared to the earlier 7.9%-12.3%.
2. The revised outlook was largely attributed to a significant macroeconomic impact of approximately $250 million in inflationary pressures for 2026. GE HealthCare specified that these cost increases were primarily driven by a substantial rise in memory chip prices, as well as elevated oil and freight costs. Additionally, tariffs adversely affected the Q1 bottom line by $0.16 per share and adjusted EBIT by $90 million. The announcement of these inflationary headwinds and the reduced guidance led to a notable stock plunge of 13% on April 30, 2026.
3. Multiple analyst downgrades and price target reductions followed GE HealthCare's Q1 2026 results and lowered guidance. On April 30, 2026, Goldman Sachs downgraded GEHC from "Buy" to "Neutral" and cut its price target from $81 to $65. Other firms, including Mizuho, JP Morgan, Citigroup, and Evercore ISI Group, also reduced their price targets, citing concerns over rising input costs, reduced earnings expectations, and broader macroeconomic exposure overshadowing other positive business drivers.
Show less
GE HealthCare Technologies (GEHC) stock has lost about 25% since 2/28/2026 because of the following key factors:
1. GE HealthCare reported a Q1 2026 earnings per share (EPS) miss and subsequently reduced its full-year 2026 profit outlook. The company announced on April 29, 2026, that its Q1 2026 adjusted EPS was $0.99, missing the consensus estimate of $1.07 by $0.08, or 7.5%. Following this, GE HealthCare cut its full-year adjusted EPS guidance to a range of $4.80-$5.00, down from its previous expectation of $4.95-$5.15. This downward revision implied a lower year-over-year growth rate for adjusted EPS, projected at 4.6%-9.0% compared to the earlier 7.9%-12.3%.
2. The revised outlook was largely attributed to a significant macroeconomic impact of approximately $250 million in inflationary pressures for 2026. GE HealthCare specified that these cost increases were primarily driven by a substantial rise in memory chip prices, as well as elevated oil and freight costs. Additionally, tariffs adversely affected the Q1 bottom line by $0.16 per share and adjusted EBIT by $90 million. The announcement of these inflationary headwinds and the reduced guidance led to a notable stock plunge of 13% on April 30, 2026.
3. Multiple analyst downgrades and price target reductions followed GE HealthCare's Q1 2026 results and lowered guidance. On April 30, 2026, Goldman Sachs downgraded GEHC from "Buy" to "Neutral" and cut its price target from $81 to $65. Other firms, including Mizuho, JP Morgan, Citigroup, and Evercore ISI Group, also reduced their price targets, citing concerns over rising input costs, reduced earnings expectations, and broader macroeconomic exposure overshadowing other positive business drivers.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -26.9% change in GEHC stock from 2/28/2026 to 6/19/2026 was primarily driven by a -19.6% change in the company's P/E Multiple.| (LTM values as of) | 2282026 | 6192026 | Change |
|---|---|---|---|
| Stock Price ($) | 84.23 | 61.59 | -26.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 20,625 | 20,979 | 1.7% |
| Net Income Margin (%) | 10.1% | 9.1% | -9.9% |
| P/E Multiple | 18.3 | 14.7 | -19.6% |
| Shares Outstanding (Mil) | 453 | 456 | -0.7% |
| Cumulative Contribution | -26.9% |
Market Drivers
2/28/2026 to 6/19/2026| Return | Correlation | |
|---|---|---|
| GEHC | -26.9% | |
| Market (SPY) | 9.2% | 51.1% |
| Sector (XLV) | -6.4% | 53.1% |
Fundamental Drivers
The -22.9% change in GEHC stock from 11/30/2025 to 6/19/2026 was primarily driven by a -16.9% change in the company's Net Income Margin (%).| (LTM values as of) | 11302025 | 6192026 | Change |
|---|---|---|---|
| Stock Price ($) | 79.92 | 61.59 | -22.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 20,246 | 20,979 | 3.6% |
| Net Income Margin (%) | 11.0% | 9.1% | -16.9% |
| P/E Multiple | 16.4 | 14.7 | -10.5% |
| Shares Outstanding (Mil) | 456 | 456 | 0.0% |
| Cumulative Contribution | -22.9% |
Market Drivers
11/30/2025 to 6/19/2026| Return | Correlation | |
|---|---|---|
| GEHC | -22.9% | |
| Market (SPY) | 9.9% | 44.1% |
| Sector (XLV) | -4.4% | 50.0% |
Fundamental Drivers
The -12.5% change in GEHC stock from 5/31/2025 to 6/19/2026 was primarily driven by a -17.5% change in the company's Net Income Margin (%).| (LTM values as of) | 5312025 | 6192026 | Change |
|---|---|---|---|
| Stock Price ($) | 70.41 | 61.59 | -12.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 19,798 | 20,979 | 6.0% |
| Net Income Margin (%) | 11.0% | 9.1% | -17.5% |
| P/E Multiple | 14.7 | 14.7 | -0.2% |
| Shares Outstanding (Mil) | 457 | 456 | 0.2% |
| Cumulative Contribution | -12.5% |
Market Drivers
5/31/2025 to 6/19/2026| Return | Correlation | |
|---|---|---|
| GEHC | -12.5% | |
| Market (SPY) | 28.1% | 45.4% |
| Sector (XLV) | 14.6% | 46.8% |
Fundamental Drivers
The -22.1% change in GEHC stock from 5/31/2023 to 6/19/2026 was primarily driven by a -0.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312023 | 6192026 | Change |
|---|---|---|---|
| Stock Price ($) | 79.11 | 61.59 | -22.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 20,979 | 0.0% |
| Net Income Margin (%) | � | 9.1% | 0.0% |
| P/E Multiple | � | 14.7 | 0.0% |
| Shares Outstanding (Mil) | 455 | 456 | -0.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2023 to 6/19/2026| Return | Correlation | |
|---|---|---|
| GEHC | -22.1% | |
| Market (SPY) | 85.7% | 55.0% |
| Sector (XLV) | 22.9% | 51.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GEHC Return | - | - | 28% | 1% | 5% | -25% | 2% |
| Peers Return | 17% | -28% | 8% | 10% | 3% | -12% | -9% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 98% |
Monthly Win Rates [3] | |||||||
| GEHC Win Rate | - | - | 50% | 42% | 58% | 33% | |
| Peers Win Rate | 57% | 38% | 52% | 60% | 50% | 43% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| GEHC Max Drawdown | - | - | - | -20% | -37% | -32% | |
| Peers Max Drawdown | -17% | -41% | -28% | -21% | -25% | -26% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, SYK, BAX, ISRG, EW.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/18/2026 (YTD)
How Low Can It Go
| Event | GEHC | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -21.3% | -9.5% |
| % Gain to Breakeven | 27.1% | 10.5% |
| Time to Breakeven | 102 days | 24 days |
In The Past
GE HealthCare Technologies's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | GEHC | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -21.3% | -9.5% |
| % Gain to Breakeven | 27.1% | 10.5% |
| Time to Breakeven | 102 days | 24 days |
In The Past
GE HealthCare Technologies's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About GE HealthCare Technologies (GEHC)
```html
GE HealthCare Technologies (GEHC) is a leading global innovator in the medical field, specializing in medical technology, pharmaceutical diagnostics, and advanced digital solutions. The company is committed to enhancing healthcare worldwide, operating with a vast international reach that extends to customers in more than 160 countries.
The company's core offerings include state-of-the-art medical technology, which encompasses a wide array of equipment and tools designed for diagnostics, treatment, and patient care. GEHC also provides essential pharmaceutical diagnostics, critical for drug discovery, development, and patient management. Additionally, it develops digital solutions, such as software and data analytics, aimed at improving clinical workflows, patient outcomes, and operational efficiencies across healthcare systems.
GE HealthCare primarily serves hospitals, clinics, research institutions, and pharmaceutical companies globally. Its extensive operational infrastructure includes over 10,000 sales representatives, 8,500 field service engineers, and 43 manufacturing sites spread across 17 countries, ensuring comprehensive support and service delivery to its diverse international clientele.
```AI Analysis | Feedback
Here are a few brief analogies for GE HealthCare Technologies (GEHC):
- Think of GE HealthCare as the IBM for hospitals, providing a comprehensive suite of medical technology, diagnostics, and digital solutions.
- It's like the Boeing of medical technology, manufacturing complex imaging machines and critical diagnostic tools used worldwide.
AI Analysis | Feedback
```html
- Medical Imaging Systems: GE HealthCare provides advanced diagnostic imaging equipment, including CT, MRI, PET, and X-ray systems, crucial for disease detection and diagnosis.
- Ultrasound Devices: The company offers a wide range of ultrasound systems for various clinical applications, such as cardiovascular, women's health, and general imaging.
- Patient Monitoring & Life Care Solutions: GE HealthCare develops devices for continuous patient monitoring, anesthesia delivery, respiratory support, and infant care in critical settings.
- Pharmaceutical Diagnostics: This segment includes contrast media and radiopharmaceuticals that are used to enhance the clarity and effectiveness of diagnostic imaging procedures.
- Digital & AI Solutions: GE HealthCare offers software platforms, data analytics, and artificial intelligence applications designed to optimize clinical workflows, improve operational efficiency, and support clinical decision-making.
AI Analysis | Feedback
Major Customers of GE HealthCare Technologies (GEHC)
GE HealthCare Technologies (GEHC) primarily sells its medical technology, pharmaceutical diagnostics, and digital solutions to other companies and institutions, not directly to individuals.
Due to the nature of its global business and extensive customer base across more than 160 countries, GE HealthCare serves thousands of hospitals, clinics, and research institutions. Specific names of individual "major" customer companies are generally not publicly disclosed by GEHC, as their revenue is diversified across a vast number of clients rather than concentrated in a few.
However, the major categories of institutional customers that GE HealthCare serves include:
- Hospitals and Healthcare Systems: This is the primary customer segment, encompassing a wide range of public and private hospitals, academic medical centers, and large integrated delivery networks (IDNs) globally. These institutions purchase GEHC's medical imaging equipment (such as MRI, CT, X-ray, ultrasound), patient monitoring systems, and various digital health solutions.
- Diagnostic Imaging Centers and Clinics: Standalone diagnostic centers, specialized clinics (e.g., cardiology, oncology clinics), and outpatient facilities are significant customers, acquiring GEHC's advanced imaging and diagnostic equipment to provide specialized services.
- Pharmaceutical and Biotechnology Companies: These companies utilize GEHC's pharmaceutical diagnostics and life sciences solutions for drug discovery, development, manufacturing processes, and quality control, including bioprocessing technologies and research tools.
AI Analysis | Feedback
null
AI Analysis | Feedback
Peter J. Arduini, President and Chief Executive Officer
Peter J. Arduini has served as President and Chief Executive Officer of GE HealthCare since January 2022, leading its spin-off from GE in January 2023, which was among the largest in med-tech history. He previously spent 15 years with GE HealthCare in various senior leadership roles, including general manager for the global Imaging business. Prior to rejoining GE HealthCare, he was president and CEO of Integra LifeSciences from 2012 to 2022. He also served as corporate vice president and president of Medication Delivery at Baxter Healthcare. Arduini began his career in sales and marketing at Procter and Gamble. He serves on the boards of GE HealthCare, Bristol-Myers Squibb Company, and the Advanced Medical Technology Association (AdvaMed), where he was named Chair of the Board of Directors in December 2023.
James Saccaro, Vice President and Chief Financial Officer
James Saccaro serves as the Vice President and Chief Financial Officer of GE HealthCare. He was previously listed as the Chief Financial Officer for GE Healthcare.
Betty Larson, Chief People Officer
Betty Larson is the Chief People Officer at GE HealthCare.
Frank Jimenez, General Counsel and Corporate Secretary
Frank Jimenez serves as the General Counsel and Corporate Secretary of GE HealthCare. He previously held the title of Vice President & General Counsel.
Roland Rott, President and CEO, Imaging
Roland Rott will assume the role of President and CEO of Imaging, effective July 1, 2024. He joined GE HealthCare in 2011 and has held multiple leadership roles within Ultrasound, ultimately becoming president and CEO of Ultrasound in 2021. Prior to joining GE HealthCare, Roland Rott worked as an executive committee member at a publicly traded company and founded two software companies that were acquired by strategic investors.
AI Analysis | Feedback
The key risks to GE HealthCare Technologies (GEHC) include:
- Supply Chain Disruptions and Cost Pressures: GE HealthCare, as an industrial company, is heavily reliant on global supply chains for its manufacturing and operations. Disruptions stemming from events such as pandemics or tariffs can significantly impede the company's ability to fulfill orders and can lead to increased costs of products and services. Recent instability due to US tariffs has already put pressure on margins and financial guidance, leading to reductions in EBIT margin and adjusted earnings per share forecasts. Furthermore, industry-wide shortages of critical components like semiconductor chips and raw materials can restrict manufacturing and drive up costs.
- Regulatory and Compliance Risks: Operating in the highly regulated medical technology sector, GE HealthCare faces substantial legal and regulatory risks. Non-compliance with applicable laws or regulations, or a determination that its products pose an unreasonable risk, can lead to severe consequences. These include the refusal or withdrawal of regulatory authorizations, product bans, detentions, recalls, imposition of operating restrictions, and significant civil or criminal penalties. The company is subject to increasing and more stringent regulations globally, and changes in legislation could impact its operations and financial performance. Additionally, violations of anti-corruption laws could result in exclusion from government healthcare programs.
- Cybersecurity Risks: The increasing integration of connected healthcare solutions and digital technologies introduces significant cybersecurity threats for GE HealthCare. Hospitals are frequently targeted for large data breaches, and personal health information holds a high value on the black market, making the healthcare sector a prime target. Cybersecurity threats can compromise systems, networks, and data, potentially harming the company's reputation and business operations. Specific vulnerabilities have been identified in GE HealthCare's imaging, ultrasound devices, and patient monitors, which could allow unauthorized remote access, data corruption, or even manipulation of critical device functions like alarms.
AI Analysis | Feedback
- Specialized artificial intelligence (AI) and software startups are emerging with highly focused, often superior, solutions for medical image analysis, diagnostics, and workflow optimization. These agile companies, specializing in specific algorithms and applications, pose a threat to GE HealthCare's broader "digital solutions" segment by offering more targeted or cost-effective alternatives that can integrate with existing hardware, potentially commoditizing GE HealthCare's own software offerings.
- Major technology companies (e.g., Amazon, Google, Microsoft) are aggressively expanding their presence in healthcare information technology and digital platforms. Leveraging their strengths in cloud computing, advanced AI, and data analytics, these tech giants are developing comprehensive healthcare ecosystems that could disintermediate GE HealthCare's "digital solutions" by offering alternative platforms for data management, predictive analytics, and patient engagement, thereby shifting control of critical digital infrastructure away from traditional medical device manufacturers.
AI Analysis | Feedback
GE HealthCare Technologies (symbol: GEHC) operates in several key addressable markets for its main products and services. The company's total addressable market (TAM) was estimated at $84 billion globally in 2021 and is projected to grow to approximately $100 billion by 2025.
Here's a breakdown of the addressable markets for its primary product divisions:
- Medical Imaging: This division includes molecular imaging, computed tomography (CT), magnetic resonance imaging (MRI), women's health screening, and X-ray systems. The global medical imaging market is estimated to grow from $28 billion in 2021 to $47.4 billion by 2030.
- Ultrasound: The global ultrasound devices market was valued at approximately $9.79 billion in 2023 and is anticipated to reach $13.07 billion by 2030. Another estimate places the global market at $10.32 billion in 2025, projected to reach $19.51 billion by 2034. North America held the largest revenue share in the ultrasound market in 2023, accounting for over 29.75%. The North American market specifically was valued at $3.00 billion in 2025.
- Patient Care Solutions: This segment focuses on patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care. The global patient monitoring devices market was valued at $63.94 billion in 2025 and is projected to grow to $134.63 billion by 2035. Another report estimates the global patient monitoring devices market at $48.5 billion in 2024, with a projection to reach $71.1 billion by 2029. North America dominated the global patient monitoring market in 2024. The North American market accounted for 42.5% of the global market in 2025, with the U.S. market specifically valued at $20.2 billion in the same year. A subset, the global digital patient monitoring devices market, was estimated at $12.94 billion in 2024 and is anticipated to reach approximately $122.75 billion by 2034.
- Pharmaceutical Diagnostics: This division manufactures contrast agents and radiopharmaceuticals. The global diagnostic radiopharmaceuticals and contrast media market is estimated at $10.00 billion in 2025 and is expected to reach $13.90 billion by 2030. Another valuation for the global diagnostic radiopharmaceuticals & contrast media market was $9,884.81 million in 2025, with an expected increase to $12,239.93 million by 2032. Focusing on radiopharmaceuticals, the global market size was $6.80 billion in 2024 and is projected to reach $16.87 billion by 2033. North America holds the largest share in the global diagnostic radiopharmaceuticals and contrast media market and is expected to maintain its dominance.
AI Analysis | Feedback
GE HealthCare Technologies (GEHC) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:
- Innovation and New Product Launches in Advanced Imaging and AI-Driven Solutions: GE HealthCare is heavily investing in research and development, with significant new product introductions anticipated to contribute meaningfully to revenue starting in 2027. Key innovations include the Photonova photon-counting CT, with orders expected in 2026 and substantial revenue impact in 2027, and advancements in total-body PET technology. The company also plans next-generation MR and photon-counting CT systems for late 2025 and into 2026, alongside a full ultrasound platform refresh featuring integrated AI. Additionally, the radiopharmaceutical Flyrcado (flurpiridaz F 18) injection is projected to generate over $500 million in revenue by year-end 2028.
- Robust Order Growth and Record Backlog: The company has consistently reported strong organic order growth and exited Q4 2025 with a record backlog of $21.8 billion, which provides significant sales visibility for future revenue. This strong demand is particularly evident in the U.S. and EMEA markets, with a solid book-to-bill ratio indicating a healthy pipeline of future business.
- Expansion in Pharmaceutical Diagnostics (PDx) and Strategic Acquisitions: GE HealthCare's Pharmaceutical Diagnostics segment has demonstrated strong organic growth, with a 12.7% increase in Q4 2025. This growth is being further enhanced by strategic acquisitions, such as the Nihon Medi-Physics (NMP) acquisition in Q1 2025, aimed at boosting global access to advanced radiopharmaceuticals. The planned acquisition of Intelerad is also expected to add approximately $270 million in annual revenue, growing in the low double digits, and accelerate GE HealthCare's "cloud-first imaging ecosystem."
- Operational Improvements and Commercial Excellence: The company is focused on driving revenue growth and margin expansion through commercial execution, productivity initiatives, and disciplined price management. Management has highlighted the "Heartbeat business system" as a foundation for productivity and margin expansion. These operational improvements are expected to contribute to earnings growth and enable further investment in key growth areas.
AI Analysis | Feedback
Share Repurchases
- In 2025, GE HealthCare completed $200 million in share repurchases under a buyback plan announced on April 30, 2025.
Share Issuance
- On January 4, 2023, GE HealthCare's common stock began trading on Nasdaq following its tax-free spin-off from General Electric, with GE shareholders receiving one share of GE HealthCare for every three shares of GE common stock held.
- Approximately 453.9 million shares of common stock were outstanding as of January 31, 2023, after the spin-off.
Inbound Investments
- Capital Research Global Investors increased its stake in GE HealthCare by 25.0% in the third quarter, acquiring 4,998,154 shares to own 24,972,556 shares worth approximately $1.875 billion.
- Institutional investors collectively own approximately 82.06% of the company's stock.
Outbound Investments
- In 2024, GE HealthCare acquired MIM Software for AI-enabled image analysis and workflow tools, and Intelligent Ultrasound for real-time image recognition technology.
- The company made strategic acquisitions in 2023 to bolster its market position.
- GE HealthCare focuses on strategic, accretive mergers and acquisitions (M&A) to fill portfolio gaps and enhance digital and AI capabilities.
Capital Expenditures
- Capital expenditures for the full year 2025 were $482 million, an increase from $401 million in 2024.
- In 2023, GE HealthCare invested over $1 billion in Research & Development (R&D) for future growth.
- The company anticipates strong capital expenditure trends in 2026, supported by recovery indicators in China, with R&D and innovation investments remaining a priority.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 83.35 |
| Mkt Cap | 76.1 |
| Rev LTM | 16,150 |
| Op Inc LTM | 2,936 |
| FCF LTM | 2,177 |
| FCF 3Y Avg | 1,622 |
| CFO LTM | 2,694 |
| CFO 3Y Avg | 2,277 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.6% |
| Rev Chg 3Y Avg | 7.6% |
| Rev Chg Q | 8.6% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Inc Chg LTM | 8.3% |
| Op Inc Chg 3Y Avg | 10.4% |
| Op Mgn LTM | 19.5% |
| Op Mgn 3Y Avg | 19.2% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 20.7% |
| CFO/Rev 3Y Avg | 17.3% |
| FCF/Rev LTM | 16.1% |
| FCF/Rev 3Y Avg | 13.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 76.1 |
| P/S | 3.7 |
| P/Op Inc | 26.0 |
| P/EBIT | 18.6 |
| P/E | 28.2 |
| P/CFO | 17.9 |
| Total Yield | 3.0% |
| Dividend Yield | 0.7% |
| FCF Yield 3Y Avg | 3.4% |
| D/E | 0.2 |
| Net D/E | 0.1 |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| ANDA215955 | REGADENOSON | regadenoson | solution | 8052024 | 6.7% | 7.4% | -13.1% | -24.2% | -24.2% |
| NDA212155 | CERIANNA | fluoroestradiol f-18 | solution | 5202020 | |||||
| ANDA210016 | CLARISCAN | gadoterate meglumine | solution | 11012019 | |||||
| NDA203137 | VIZAMYL | flutemetamol f-18 | injectable | 10252013 | |||||
| NDA022454 | DATSCAN | ioflupane i-123 | solution | 1142011 | |||||
| NDA022290 | ADREVIEW | iobenguane sulfate i-123 | solution | 9192008 | |||||
| NDA022066 | OMNISCAN | gadodiamide | injectable | 9052007 | |||||
| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| ANDA215955 | REGADENOSON | regadenoson | solution | 8052024 | 6.7% | 7.4% | -13.1% | -24.2% | -24.2% |
| NDA212155 | CERIANNA | fluoroestradiol f-18 | solution | 5202020 | |||||
| ANDA210016 | CLARISCAN | gadoterate meglumine | solution | 11012019 | |||||
| NDA203137 | VIZAMYL | flutemetamol f-18 | injectable | 10252013 | |||||
| NDA022454 | DATSCAN | ioflupane i-123 | solution | 1142011 | |||||
| NDA022290 | ADREVIEW | iobenguane sulfate i-123 | solution | 9192008 | |||||
| NDA022066 | OMNISCAN | gadodiamide | injectable | 9052007 | |||||
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Imaging | 9,245 | 8,855 | 8,944 | 9,985 | 9,433 |
| Advanced Visualization Solutions (AVS) | 5,354 | 5,131 | 5,094 | 3,422 | 3,172 |
| Patient Care Solutions (PCS) | 3,086 | 3,125 | 3,142 | 2,916 | 2,915 |
| Pharmaceutical Diagnostics (PDx) | 2,900 | 2,508 | 2,306 | 1,958 | 2,018 |
| Other | 40 | 52 | 66 | 60 | 47 |
| Total | 20,625 | 19,671 | 19,552 | 18,341 | 17,585 |
| $ Mil | 2022 | 2021 |
|---|---|---|
| Imaging | 1,100 | |
| Advanced Visualization Solutions (AVS) | 908 | |
| Pharmaceutical Diagnostics (PDx) | 520 | |
| Patient Care Solutions (PCS) | 341 | |
| Non-operating benefit income (costs) | 5 | |
| Other | -8 | |
| Interest and other financial charges – net | -77 | |
| Amortization of acquisition-related intangible assets | -121 | |
| Restructuring costs | -146 | 155 |
| Total | 2,522 | 155 |
Price Behavior
Price Behavior
| Market Price | $61.59 | |
| Market Cap ($ Bil) | 28.1 | |
| First Trading Date | 01/04/2023 | |
| Distance from 52W High | -30.1% | |
| 50 Days | 200 Days | |
| DMA Price | $65.40 | $74.60 |
| DMA Trend | down | down |
| Distance from DMA | -5.8% | -17.4% |
| 3M | 1YR | |
| Volatility | 40.5% | 32.5% |
| Downside Capture | 222.71 | 163.09 |
| Upside Capture | 77.45 | 101.15 |
| Correlation (SPY) | 44.4% | 44.7% |
GEHC Betas & Captures as of 5/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.50 | 2.06 | 1.65 | 1.33 | 1.27 | 1.18 |
| Up Beta | 3.34 | 2.53 | 2.31 | 1.54 | 1.38 | 1.11 |
| Down Beta | 2.71 | -0.23 | 0.56 | 0.92 | 0.96 | 1.31 |
| Up Capture | 55% | 52% | 67% | 87% | 105% | 87% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 10 | 19 | 28 | 61 | 129 | 373 |
| Down Capture | 71% | 473% | 247% | 170% | 142% | 107% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 10 | 22 | 35 | 63 | 121 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GEHC | |
|---|---|---|---|---|
| GEHC | -13.3% | 32.4% | -0.41 | - |
| Sector ETF (XLV) | 14.0% | 15.0% | 0.66 | 46.3% |
| Equity (SPY) | 26.5% | 12.4% | 1.61 | 45.0% |
| Gold (GLD) | 24.2% | 27.5% | 0.77 | 12.0% |
| Commodities (DBC) | 19.8% | 18.8% | 0.83 | -30.2% |
| Real Estate (VNQ) | 11.0% | 13.7% | 0.52 | 40.4% |
| Bitcoin (BTCUSD) | -40.0% | 42.5% | -1.08 | 15.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GEHC | |
|---|---|---|---|---|
| GEHC | 0.5% | 32.4% | 0.06 | - |
| Sector ETF (XLV) | 5.4% | 14.7% | 0.19 | 48.9% |
| Equity (SPY) | 13.5% | 17.1% | 0.62 | 53.4% |
| Gold (GLD) | 17.1% | 18.3% | 0.76 | 10.8% |
| Commodities (DBC) | 7.5% | 19.4% | 0.29 | 2.3% |
| Real Estate (VNQ) | 1.9% | 18.9% | 0.00 | 43.9% |
| Bitcoin (BTCUSD) | 11.0% | 54.2% | 0.40 | 12.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GEHC | |
|---|---|---|---|---|
| GEHC | 0.2% | 32.4% | 0.06 | - |
| Sector ETF (XLV) | 9.4% | 16.6% | 0.46 | 48.9% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 53.4% |
| Gold (GLD) | 12.3% | 16.1% | 0.63 | 10.8% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | 2.3% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | 43.9% |
| Bitcoin (BTCUSD) | 60.0% | 66.8% | 1.00 | 12.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/29/2026 | -13.2% | -10.9% | -8.2% |
| 2/4/2026 | 4.9% | 0.6% | -2.1% |
| 10/29/2025 | -2.5% | -6.4% | 1.5% |
| 7/30/2025 | -7.8% | -9.0% | -4.5% |
| 4/30/2025 | 3.3% | -1.5% | 5.1% |
| 2/13/2025 | 8.8% | 7.2% | -4.6% |
| 10/30/2024 | 2.3% | 3.4% | -2.7% |
| 7/31/2024 | 2.4% | -1.3% | 1.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 6 | 6 |
| # Negative | 6 | 8 | 8 |
| Median Positive | 4.1% | 5.3% | 6.1% |
| Median Negative | -8.1% | -7.2% | -6.4% |
| Max Positive | 11.6% | 13.3% | 26.8% |
| Max Negative | -14.3% | -10.9% | -14.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/29/2026 | -13.2% | -10.9% | -8.2% |
| 2/4/2026 | 4.9% | 0.6% | -2.1% |
| 10/29/2025 | -2.5% | -6.4% | 1.5% |
| 7/30/2025 | -7.8% | -9.0% | -4.5% |
| 4/30/2025 | 3.3% | -1.5% | 5.1% |
| 2/13/2025 | 8.8% | 7.2% | -4.6% |
| 10/30/2024 | 2.3% | 3.4% | -2.7% |
| 7/31/2024 | 2.4% | -1.3% | 1.5% |
| 4/30/2024 | -14.3% | -10.3% | -11.8% |
| 2/6/2024 | 11.6% | 13.3% | 26.8% |
| 10/31/2023 | 5.4% | 12.5% | 7.2% |
| 7/25/2023 | -0.5% | -3.3% | -14.5% |
| 4/25/2023 | -8.4% | -8.0% | -12.0% |
| 1/30/2023 | 2.0% | 0.7% | 8.4% |
| SUMMARY STATS | |||
| # Positive | 8 | 6 | 6 |
| # Negative | 6 | 8 | 8 |
| Median Positive | 4.1% | 5.3% | 6.1% |
| Median Negative | -8.1% | -7.2% | -6.4% |
| Max Positive | 11.6% | 13.3% | 26.8% |
| Max Negative | -14.3% | -10.9% | -14.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/29/2026 | 10-Q |
| 12/31/2025 | 02/04/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/13/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/06/2024 | 10-K |
| 09/30/2023 | 10/31/2023 | 10-Q |
| 06/30/2023 | 07/25/2023 | 10-Q |
| 03/31/2023 | 04/25/2023 | 10-Q |
| 12/31/2022 | 02/15/2023 | 10-K |
| 09/30/2022 | 12/02/2022 | 10-12B/A |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/29/2026 | 10-Q |
| 12/31/2025 | 02/04/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/13/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/06/2024 | 10-K |
| 09/30/2023 | 10/31/2023 | 10-Q |
| 06/30/2023 | 07/25/2023 | 10-Q |
| 03/31/2023 | 04/25/2023 | 10-Q |
| 12/31/2022 | 02/15/2023 | 10-K |
| 09/30/2022 | 12/02/2022 | 10-12B/A |
Recent Forward Guidance
Updated 5/31/2026Latest: Q1 2026 Earnings Reported 4/29/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Organic revenue growth | 3.0% | 3.5% | 4.0% | 0 | 0 | Affirmed | Guidance: 3.5% for 2026 |
| 2026 Adjusted EBIT margin | 15.4% | 15.55% | 15.7% | -2.5% | -0.4% | Lowered | Guidance: 15.95% for 2026 |
| 2026 Adjusted effective tax rate | 20.0% | 20.5% | 21.0% | 0 | Affirmed | Guidance: 20.5% for 2026 | |
| 2026 Adjusted EPS | 4.95 | 4.9 | 5.15 | -3.0% | Lowered | Guidance: 5.05 for 2026 | |
| 2026 Free cash flow | 1.60 Bil | -5.9% | Lowered | Guidance: 1.70 Bil for 2026 | |||
Prior: Q4 2025 Earnings Reported 2/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Organic Revenue Growth | 3.0% | 3.5% | 4.0% | 16.7% | Higher New | Actual: 3.0% for 2025 | |
| 2026 Adjusted EBIT Margin | 15.8% | 15.95% | 16.1% | 4.2% | 0.6% | Higher New | Actual: 15.3% for 2025 |
| 2026 Adjusted Effective Tax Rate | 20.0% | 20.5% | 21.0% | 0 | Same New | Actual: 20.5% for 2025 | |
| 2026 Adjusted EPS | 4.95 | 5.05 | 5.15 | 10.5% | Higher New | Actual: 4.57 for 2025 | |
| 2026 Free Cash Flow | 1.70 Bil | 21.4% | Higher New | Actual: 1.40 Bil for 2025 | |||
Insider Activity
Updated 5/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lobo, Kevin | Direct | Buy | 5262026 | 64.18 | 10,000 | 641,800 | 921,817 | Form | |
| 2 | Hochman, Rodney F | family trust | Buy | 5132026 | 62.03 | 1,618 | 100,365 | 100,365 | Form | |
| 3 | Yang, Watkin Phoebe L | Direct | Buy | 5112026 | 63.01 | 1,000 | 63,006 | 863,312 | Form | |
| 4 | Stromberg, William J | Direct | Buy | 5072026 | 61.69 | 1,000 | 61,689 | 945,695 | Form | |
| 5 | Culp, H Lawrence JR | holding company | Buy | 5072026 | 61.88 | 80,805 | 5,000,076 | 9,356,432 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lobo, Kevin | Direct | Buy | 5262026 | 64.18 | 10,000 | 641,800 | 921,817 | Form | |
| 2 | Hochman, Rodney F | family trust | Buy | 5132026 | 62.03 | 1,618 | 100,365 | 100,365 | Form | |
| 3 | Yang, Watkin Phoebe L | Direct | Buy | 5112026 | 63.01 | 1,000 | 63,006 | 863,312 | Form | |
| 4 | Stromberg, William J | Direct | Buy | 5072026 | 61.69 | 1,000 | 61,689 | 945,695 | Form | |
| 5 | Culp, H Lawrence JR | holding company | Buy | 5072026 | 61.88 | 80,805 | 5,000,076 | 9,356,432 | Form | |
| 6 | Saccaro, James | Chief Financial Officer | Direct | Buy | 5012026 | 60.60 | 3,310 | 200,585 | 5,300,716 | Form |
| 7 | Jimenez, Frank R | GC & Corporate Secretary | Direct | Buy | 4302026 | 60.45 | 1,750 | 105,788 | 5,678,189 | Form |
| 8 | Arduini, Peter J | President and CEO | Direct | Buy | 4302026 | 59.92 | 4,169 | 249,827 | 15,545,983 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/19/2026